Skip to content

CapEx at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$347M+33.5%
Eli Lilly logo
Eli LillyLLY
$2.33B+54.0%
Pfizer logo
PfizerPFE
$436M-22.7%
Merck & Co. logo
Merck & Co.MRK
$991M-25.4%
Amgen logo
AmgenAMGN
$712M+73.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$69K

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$40.63B+495%
Enterprise value$40.35B+515%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revolution Medicines, Inc.'s capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revolution Medicines, Inc.'s capex?
Revolution Medicines, Inc. (RVMD) reported capex of $1.54M in Q1 2026.
How has Revolution Medicines, Inc.'s capex changed year-over-year?
Revolution Medicines, Inc.'s capex decreased by 52.9% year-over-year, from $3.27M to $1.54M.
What is the long-term trend for Revolution Medicines, Inc.'s capex?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s capex has grown at a 25.1% compound annual growth rate (CAGR), from $6.53M to $15.99M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.